Nephros (NEPH) Asset Writedowns and Impairment (2015 - 2026)

Nephros' Asset Writedowns and Impairment history runs 12 years deep, the most recent figure standing at $11000.0 for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment rose 83.33% year-over-year to $11000.0; the TTM figure through Mar 2026 stood at $73000.0 (down 62.56% YoY), while the FY2025 annual figure was $68000.0, down 74.05% from the prior year.
• Asset Writedowns and Impairment was $11000.0 for Q1 2026 at Nephros, down from $12000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $1.3 million in Q3 2022 to a low of -$1.4 million in Q4 2022.
• Historically, Asset Writedowns and Impairment has averaged $37352.9 across 5 years, with a median of $35000.0 in 2025.
• Biggest YoY gain for Asset Writedowns and Impairment was 1396.51% in 2022; the steepest drop was 1651.11% in 2022.
• A 5-year view of Asset Writedowns and Impairment shows it stood at -$1.4 million in 2022, then jumped by 120.13% to $281000.0 in 2023, then plunged by 82.92% to $48000.0 in 2024, then tumbled by 75.0% to $12000.0 in 2025, then retreated by 8.33% to $11000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $11000.0 (Q1 2026), $12000.0 (Q4 2025), and $15000.0 (Q3 2025), per Business Quant data.